Medtronic (MDT) announced “MiniMed” as the name for the planned new diabetes company following the intended separation. The name honors the company’s roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world. Medtronic is targeting completion of the planned separation within 18 months of the initial announcement, subject to customary conditions and legal requirements including consultations with works councils and other employee representative bodies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Deutsche Bank Sounds Alarm on Intuitive Surgical Stock (ISRG) with a Rare ‘Sell’ Rating
- Medtronic’s Diabetes Division Spin-Off: Hold Rating Amid Modest Immediate Value Potential
- Largest borrow rate increases among liquid names
- Medtronic call volume above normal and directionally bullish
- Medtronic’s Hold Rating: Navigating Profit Decline, Innovation Challenges, and Market Threats